Evidentli, a leading Healthcare AI-enabled evidence acceleration company, today announced the appointment of Dr Claudia Suessmuth-Dyckerhoff as Chair and Dr Kaveh Safavi as Non-Executive Director, marking a major governance milestone as the company enters the final quarter of 2025 and prepares for its next growth phase in 2026.
With the expanded board, Evidentli is poised to further support health systems and pharmaceutical teams in accelerating the generation and dissemination of evidence, enabling more efficient and effective clinical trials, better real-word evidence of outcomes, insight-enabled population health actions and more efficient quality monitoring and improvement. Evidentli’s Agentic AI platform automates very rapidly - at scale and with near-perfect accuracy - the transformation of unstructured or variously structured internal and external real-world data sources to common standards such as OMOP and enables research communities with a no-code analytics workbench and an evidence hub enabling collaborative development of a library of evidence-generation enabling assets. This means that researchers and their data scientist colleagues can focus their efforts on formulating and executing research questions rather than spending their time on “data wrangling”.
“The addition of two world-class leaders to our Board brings exceptionally rich and diverse expertise in healthcare, digital transformation, and global growth to the Board”, said Evidentli Founder Guy Tsafnat.
David Champeaux, Evidentli CEO, commented, “I am delighted that Evidentli will be able to benefit from the wisdom and expert counsel of Claudia and Kaveh, who are uniquely qualified to help ensure that we deliver on our mission to enable health systems and life sciences stakeholders to improve outcomes and drive value at scale, with healthier data foundations and a better ability to generate and collaborate on evidence generation and dissemination”.
Dr Claudia Suessmuth-Dyckerhoff is recognised for her leadership in global healthcare strategy and digital transformation. Dr Kaveh Safavi brings decades of experience in clinical research, health IT, and advisory roles across the life sciences sector.
Of her appointment to Chair, Claudia says, “While we have more data in healthcare than ever, making the data usable remains the challenge and takes too much time and resources. This is one of the biggest hurdles we have to overcome before existing healthcare data can really drive patient impact. That’s why I am excited to chair the board of Evidentli, as Evidentli has a unique solution to harmonise healthcare data at near perfect accuracy, and working with management, we as a board can support the acceleration of efficiency and effectiveness in evidence generation for Pharma, health systems, healthcare analytics and AI solutions developers”.
Kaveh comments: “Our ability to maximize the benefits of artificial intelligence are directly related to accessing useful and reliable data. I am excited to be part of a company focused on addressing that mission-critical bottleneck so we can reap the rewards of better science and better care”.
Claudia and Kaveh add to Evidentli’s growth, right after recently announcing the extension of its scientific and strategic advisory board with five new members who will help refine Evidentli’s value propositions and strategic partnerships in the health and life sciences ecosystem.
With proven technology, expanding partnerships and enhanced governance, Evidentli is well positioned to leverage its extensive R&D to offer commercially-scaled health data and evidence-acceleration platform solutions, defining the next era of evidence across healthcare and life sciences ecosystems.